Project Grant K22CA299417
Award Date 5/8/26
Completion Date 4/30/29
Dollars Obligated $193K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA 22904, USA
Similar Awards
- Federal Grant Award Summary The University of Virginia received a $2.66 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded September 1, 2025, through August 31, 2030. The award supports a coordinated research initiative to develop ceramide-directed therapeutics for acute myeloid leukemia (AML) treatment. The program integrates three inter-related research projects and four essential core facilities to define the biological...
- Federal Project Grant Award Summary The National Cancer Institute awarded a Project Grant of $495,715 to the Sloan-Kettering Institute for Cancer Research under the Cancer Biology Research program (CFDA 93.396) on August 5, 2025, with a completion date of July 31, 2030. This award funds fundamental research to decipher the pathogenesis and therapeutic vulnerabilities in germline RUNX1-mutated acute myeloid leukemia (AML). The research focuses on understanding how germline RUNX1 mutations...
- Federal Grant Award Summary New York University School of Medicine received a $149,190 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025, with completion by May 6, 2027. This award supports biomedical research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The funded research project focuses on elucidating the mechanisms of DNA...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Virginia a $484,387 Project Grant on May 7, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop novel statistical methods for analyzing Enzyme-Linked Immunospot (ELISPOT) assay data. The project, which runs through April 30, 2030, addresses a critical gap in standardizing ELISPOT analysis across clinical and translational immunology studies. ELISPOT assays are widely used to quantify...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the Rector & Visitors of the University of Virginia to conduct research on the role of long noncoding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. This research will provide insights into how noncoding RNAs...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Pennsylvania a Project Grant of $148,626 under the Cancer Research Manpower program (CFDA 93.398), effective December 1, 2025, through April 30, 2028. This award supports research training and investigator development in cancer research aligned with the National Cancer Program's strategic priorities. The funding enables the institution to provide biomedical training opportunities and research career...
- Federal Project Grant Award Summary Duke University received a $302,524 Project Grant from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) awarded on September 10, 2025, with a completion date of April 30, 2028. This F32 postdoctoral fellowship award supports research investigating the role of SMARCAL1, an annealing helicase protein, in promoting glioma cell proliferation and suppressing tumor-intrinsic inflammation in alternative lengthening of...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Miami's Office of Research Administration within the School of Medicine a Project Grant totaling $109,076.00 under the Cancer Research Manpower program (CFDA 93.398) on December 17, 2025. The award supports biomedical research training and career development initiatives focused on cancer research through September 1, 2029. This project grant funds the institution's capacity to provide integrated...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $530,106 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective September 11, 2025 through August 31, 2030. The project, "Targeting Polyamine Metabolism in Relapsed Acute Myeloid Leukemia Stem Cells," focuses on fundamental research to understand and mechanistically interrogate polyamine metabolism in leukemia stem cells (LSCs). The...
- Federal Grant Award Summary The University of Pennsylvania received a $434,969 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective May 1, 2026 through April 30, 2031. This award funds research investigating Type I interferon response and differentiation mechanisms in FLT3 (Fms-like tyrosine kinase 3)-inhibitor persistent acute myeloid leukemia (AML). The project deliverables include mechanistic studies identifying which...